The authors declare that they have no competing interests.
All of the authors have made substantial contributions to the study. MH has developed the concept and design of the study, performed the statistical analysis and interpretation of data and drafted the manuscript. CH has made substantial contributions to concept of the study, data acquisition and was involved in drafting the manuscript. AT was involved in acquisition, analysis and interpretation of data. KJ has made substantial contributions to concept of the study and was involved in revising the manuscript critically and adding important content. MN has participated in the design of the study, the interpretation of data and was involved in drafting the manuscript and revising it critically and substantially. All authors have read and approved the final manuscript.
An imaging tool providing reliable prostate cancer (PCa) detection and localization is necessary to improve common diagnostic pathway with ultrasound targeted biopsies. To determine the performance of transrectal ultrasound (TRUS) augmented by prostate HistoScanningTM analysis (PHS) we investigated the detection of prostate cancer (PCa) foci in repeat prostate biopsies (Bx).
97 men with a mean age of 66.2 (44 – 82) years underwent PHS augmented TRUS analysis prior to a repeat Bx. Three PHS positive foci were defined in accordance with 6 bilateral prostatic sectors. Targeted Bx (tBx) limited to PHS positive foci and a systematic 14-core backup Bx (sBx) were taken. Results were correlated to biopsy outcome. Sensitivity, specificity, predictive accuracy, negative predictive value (NPV) and positive predictive value (PPV) were calculated.
PCa was found in 31 of 97 (32 %) patients. Detection rate in tBx was significantly higher (p < .001). Detection rate in tBx and sBx did not differ on patient level(p ≥ 0.7). PHS sensitivity, specificity, predictive accuracy, PPV and NPV were 45 %, 83 %, 80 %, 19 % and 95 %, respectively.
PHS augmented TRUS identifies abnormal prostatic tissue. Although sensitivity and PPV for PCa are low, PHS information facilitates Bx targeting to vulnerable foci and results in a higher cancer detection rate. PHS targeted Bx should be considered in patients at persistent risk of PCa.
Aigner F, Pallwein L, Schocke M, Lebovici A, Junker D, Schäfer G, et al. Comparison of Real-time Sonoelastography With T2-weighted endorectal magnetic resonance imaging for prostate cancer detection. JUM. 2011;30:643–9.
- Computer-aided transrectal ultrasound: does prostate HistoScanning™ improve detection performance of prostate cancer in repeat biopsies?
Moritz Franz Hamann
K P Jünemann
C M Naumann
- BioMed Central
Neu im Fachgebiet Urologie
Meistgelesene Bücher in der Urologie
Mail Icon II